{
    "root": "35ccef4e-f4b4-80c6-e063-6394a90ae254",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "OXCARBAZEPINE",
    "value": "20250523",
    "ingredients": [
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYVINYL ALCOHOL",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "OXCARBAZEPINE",
            "code": "VZI5B1W380",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7824"
        }
    ],
    "indications": {
        "text": "oxcarbazepine tablets indicated monotherapy adjunctive therapy treatment partial-onset seizures adults monotherapy treatment partial-onset seizures pediatric patients aged 4 years , adjunctive therapy pediatric patients aged 2 years partial-onset seizures .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "adults : initiate dose 600 mg/day , given twice day \u2022 adjunctive therapy : maximum increment 600 mg/day approximately weekly intervals . recommended daily dose 1200 mg/day ( 2.1 ) \u2022 conversion monotherapy : withdrawal concomitant 3 6 weeks ; reach maximum dose oxcarbazepine tablets 2 4 weeks increments 600 mg/day weekly intervals recommended daily dose 2400 mg/day ( 2.2 ) \u2022 initiation monotherapy : increments 300 mg/day every third day dose 1200 mg/day ( 2.3 ) \u2022 initiate one-half usual starting dose increase slowly patients creatinine clearance < 30 ml/min ( 2.7 ) pediatrics : initiation 8 10 mg/kg/day , given twice day . patients aged 2 < 4 years 20 kg , starting dose 16 20 mg/kg/day may considered . recommended daily dose dependent upon patient weight . \u2022 adjunctive patients ( aged 2 16 years ) : patients aged 4 16 years , target maintenance dose achieved 2 weeks ( 2.4 ) . patients aged 2 < 4 years , maximum maintenance dose achieved 2 4 weeks exceed 60 mg/kg/day ( 2.4 ) \u2022 conversion monotherapy patients ( aged 4 16 years ) : maximum increment 10 mg/kg/day weekly intervals , concomitant antiepileptic drugs ( aeds ) completely withdrawn 3 6 weeks ( 2.5 ) \u2022 initiation monotherapy patients ( aged 4 16 years ) : increments 5 mg/kg/day every third day ( 2.6 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "oxcarbazepine tablets , usp provided : 300 mg film-coated tablets : brown colored , oval shaped , biconvex , film coated tablets debossed ' v ' one side ' 7 ' ' 7 ' another side separated score line ( functional scoring ) sides . bottle 100 ndc 72603-271-01 bottle 500 ndc 72603-271-02 600 mg film-coated tablets : brown colored , oval shaped , biconvex , film coated tablets debossed ' v ' one side ' 7 ' ' 8 ' another side separated score line ( functional scoring ) sides . bottle 100 ndc 72603-272-01 bottle 500 ndc 72603-272-02 store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . dispense tight container ( usp ) .",
    "adverseReactions": "oxcarbazepine tablets contraindicated patients known hypersensitivity oxcarbazepine components , eslicarbazepine acetate [ ( 5.2 , 5.3 ) ] .",
    "indications_original": "Oxcarbazepine tablets are indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.",
    "contraindications_original": "Adults : initiate with a dose of 600 mg/day, given twice a day \u2022 Adjunctive Therapy: Maximum increment of 600 mg/day at approximately weekly intervals. The recommended daily dose is 1200 mg/day ( 2.1 ) \u2022 Conversion to Monotherapy: Withdrawal concomitant over 3 to 6 weeks; reach maximum dose of oxcarbazepine tablets in 2 to 4 weeks with increments of 600 mg/day at weekly intervals to a recommended daily dose of 2400 mg/day ( 2.2 ) \u2022 Initiation of Monotherapy: Increments of 300 mg/day every third day to a dose of 1200 mg/day ( 2.3 ) \u2022 Initiate at one-half the usual starting dose and increase slowly in patients with a creatinine clearance < 30 mL/min ( 2.7 ) Pediatrics : initiation with 8 to 10 mg/kg/day, given twice a day. For patients aged 2 to < 4 years and under 20 kg, a starting dose of 16 to 20 mg/kg/day may be considered. Recommended daily dose is dependent upon patient weight. \u2022 Adjunctive Patients (Aged 2 to 16 Years): For patients aged 4 to 16 years, target maintenance dose should be achieved over 2 weeks ( 2.4 ). For patients aged 2 to < 4 years, maximum maintenance dose should be achieved over 2 to 4 weeks and should not exceed 60 mg/kg/day ( 2.4 ) \u2022 Conversion to Monotherapy for Patients (Aged 4 to 16 Years): Maximum increment of 10 mg/kg/day at weekly intervals, concomitant antiepileptic drugs (AEDs) can be completely withdrawn over 3 to 6 weeks ( 2.5 ) \u2022 Initiation of Monotherapy for Patients (Aged 4 to 16 Years): Increments of 5 mg/kg/day every third day ( 2.6 )",
    "warningsAndPrecautions_original": "Oxcarbazepine Tablets, USP are provided as: \n  \n                     300 mg Film-Coated Tablets:Brown colored, oval shaped, biconvex, film coated tablets debossed with 'V' on one side and '7' and '7' on another side separated by a score line (functional scoring) on both sides. \n    Bottle of 100\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 72603-271-01 \n    Bottle of 500\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 72603-271-02 \n  \n                     600 mg Film-Coated Tablets:Brown colored, oval shaped, biconvex, film coated tablets debossed with 'V' on one side and '7' and '8' on another side separated by a score line (functional scoring) on both sides. \n    Bottle of 100\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 72603-272-01 \n    Bottle of 500\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 72603-272-02 \n    Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. Dispense in tight container (USP).",
    "adverseReactions_original": "Oxcarbazepine tablets are contraindicated in patients with a known hypersensitivity to oxcarbazepine or to any of its components, or to eslicarbazepine acetate [\n \n  see Warnings and Precautions (\n  \n   5.2,\n  \n   5.3)\n \n  ].",
    "drug": [
        {
            "name": "OXCARBAZEPINE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7824"
        }
    ]
}